Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21306780 | 1.00 | SCN9A (0.50) | SCN9ADRD2HTR2C | |
| SCHEMBL23639030 | 0.84 | SCN9A (0.49) | SCN9ADRD2HTR2C | |
| SCHEMBL23638950 | 0.82 | SCN9A (0.48) | SCN9ADRD2HTR2C | |
| SCHEMBL21306739 | 0.82 | HTR2C (0.43) | SCN9ADRD2HTR2C | |
| SCHEMBL21294928 | 0.82 | HTR2C (0.43) | SCN9ADRD2HTR2C | |
| SCHEMBL21294734 | 0.82 | HTR2C (0.43) | SCN9ADRD2HTR2C | |
| SCHEMBL23639026 | 0.81 | SCN9A (0.47) | SCN9ADRD2HTR2C | |
| SCHEMBL21307045 | 0.81 | SCN9A (0.49) | SCN9AHTR2C | |
| SCHEMBL21294883 | 0.81 | SCN9A (0.49) | SCN9AHTR2C | |
| SCHEMBL28487582 | 0.78 | SCN9A (0.49) | SCN9ADRD2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| CN-112041313-A | Pyridine-sulfonamide compounds and their use against pain and related conditions | 基因泰克公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | ASAH2, ACER2, PCSK9 | SCN9A 2136/4885DRD2 3912/4885HTR2C 2475/4885 |
| US-20220081423-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | TRPV1, HCN4, TRPA1 | SCN9A 90/4885DRD2 2128/4885HTR2C 823/4885 |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | TRPV1, HCN4, TRPA1 | SCN9A 90/4885DRD2 2128/4885HTR2C 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.